Effectiveness of Biologic Agents Among Hispanic Patients With Metastatic Colorectal Cancer.

ABSTRACT:

Background

Randomized clinical trials have defined the survival advantage with the addition of biologic drugs to chemotherapy in patients with metastatic colorectal cancer (mCRC). Under representation of Hispanics contributes to poorly defined outcomes in this group. We aim to determine whether the real-world benefit of biologics extends to Hispanics using a comparative effectiveness research approach.

Methods

This retrospective cohort study included all treatment centers contributing to SEER registry with available claims in the SEER-Medicare linked database (2001-2011) and 2 hospitals (2004-2016) catering to minorities. Metastatic CRC patients were classified as receiving chemotherapy or biochemotherapy (CT plus biologics; if initiated within 3 months of chemotherapy). The

SUBMITTER: Patel R 

PROVIDER: S-EPMC10922547 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature